MSB

2.70%

95.0¢ mesoblast limited

Are you suggesting that Dr Itescu is negligent or corrupt in his...

First 17891 Last

Share
Profile

Follow
Wilba32

6,816 Posts.

1474

11/08/24

13:33

Post #: 75158312
Share

Originally posted by JB1975: ↑

I picked up your reference - col69 (a person who I'd hope has a below decks cabin) on this ship - and be handcupped to quite a few others - constantly flogs that line - do you remember the original post of mine that actually did think there was a typo even.

I say this because you have been a person who is short and pithy with their posts and doesn't normally attack other posters - you have been rare on hotcopper in that on balance I think your contribution has been positive not self indulgent.

In vivo and in vitro are not used inappropriately in my view in this post - reg's faith that the IL-2R potency assay wasn't used before though is clearly incorrect as any checking of the MSB submission to ODAC using the wayback machine can make clear - MSB has ALWAYS used both TNFR1 and Il2Ralpha.

I am watching the patent applications - an application is not a patent granted. It seems that if I don't post for a while people that don't even tick if I reply to their questions start to try to use some of what I've taught them.

My attitude - there is a lot of people that are going to deserve what they get that are holders on this forum. Character matters.

People of low character - set the bar low.

I'll ask this as a question - Silviu Itsecu was looking for a BLA in August 2020 and got a CRL in October 2020. Eric Rose made public information about a potency assay having problems in May 2022 (could have been 3).

Two questions - do you think Silviu would have been ignorant of the potency assay problem Eric spoke about in May years later at the time of ODAC? Do you think he would have not gone ahead and shipped product that may not have been potent to children even if he was confident its wasn't harmful?

The financial incentives here are a problem in my opinion when coupled to the character of the man. I think the FDA should not dare trust him. He should have to produce evidence ahead of not after a granted BLA because of how he conducts himself in the public sphere. That is my opinion. He can't be trusted to do the right thing - on his own honor- unless he is under close scrutiny to ensure he does. And overwhelmingly that also applies to his supporters here. Medicines would be crap if the objectivity of MSB holders was the standard. The holders themselves would get crap when they need it because their own standards of decency and objectivity - generalised over other people - would have killed them.

Expand

Are you suggesting that Dr Itescu is negligent or corrupt in his profession and that he should not be trusted by the US Food and Drug Administration.

Evidence (not your thinking) please as to why the FDA dare not trust him.

Last edited by Wilba32: Today, 13:33

MSB Price at posting: 95.0¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Emerald & Azure score Digger & Dealer awards

Bitcoin: Current State of Play & Where to Next | Swyftx

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

TKM

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

TNC

True North increases silver metal at QLD's Vero deposit by 20%

HZR

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

NEU

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Revolutionary inverter technology leads the clean energy charge

There are more pages in this discussion • 5 more messages in this thread...

First 17891 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 95.0¢		Change 0.025(2.70%)		Mkt cap ! $1.084B

Open	High	Low	Value	Volume
94.0¢	96.8¢	93.5¢	$4.207M	4.417M

Buyers (Bids)

No.	Vol.	Price($)
3	42268	94.0¢

Sellers (Offers)

Price($)	Vol.	No.
95.0¢	48002	3

View Market Depth

No.	Vol.	Price($)
2	41000	0.940
4	39720	0.935
1	20000	0.930
6	60000	0.925
2	431086	0.920

Price($)	Vol.	No.
0.950	30347	2
0.955	20000	1
0.960	47000	2
0.965	35223	3
0.970	259286	4

Last trade - 16.10pm 09/08/2024 (20 minute delay)

MSB (ASX) Chart

Are you suggesting that Dr Itescu is negligent or corrupt in his...

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Emerald & Azure score Digger & Dealer awards

Bitcoin: Current State of Play & Where to Next | Swyftx

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

True North increases silver metal at QLD's Vero deposit by 20%

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Revolutionary inverter technology leads the clean energy charge

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Are you suggesting that Dr Itescu is negligent or corrupt in his...

Top Stories

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Emerald & Azure score Digger & Dealer awards

Bitcoin: Current State of Play & Where to Next | Swyftx

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

True North increases silver metal at QLD's Vero deposit by 20%

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Revolutionary inverter technology leads the clean energy charge

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News